Zyvox / Linezolid

- See: Zyvox Commercial Web Site

- Discussion: 
    - for MRSA and staph epi infections;
    - dose: 600 mg PO bid;
    - in standard dosing, the plasma and tissue levels will be between 10-11 mcg/ml (about 4 mcg/ml in bone);
    - mao inhibitors
          - linezolid is a reversible, nonselective inhibitor of monoamine oxidase;
          - linezolid has the potential for interaction with adrenergic and serotonergic agents;
    - side effects include myelo - suppression, peripheral neuropathy, and optic nerve issues;

- References:
    - Successful treatment of chronic bone and joint infections with oral linezolid.

    - Linezolid in the Treatment of Implant-related Chronic Osteomyelitis.
    - Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA). 

    - Safety and tolerability of linezolid. 



Original Text by Clifford R. Wheeless, III, MD.

Last updated by Data Trace Staff on Tuesday, October 31, 2017 6:57 am